List of Vancomycin drug patents
Vancomycin is owned by Xellia Pharms Aps.
Vancomycin contains Vancomycin.
Vancomycin has a total of 4 drug patents out of which 0 drug patents have expired.
Vancomycin was authorised for market use on 26 August, 2021.
Vancomycin is available in solution;intravenous, oral dosage forms.
Vancomycin can be used as method of treating bacterial infections.
The generics of Vancomycin are possible to be released after 06 November, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188697 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
| US10039804 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
| US11000567 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
| US10849956 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
Drugs and Companies using VANCOMYCIN ingredient
Market Authorisation Date: 26 August, 2021
Treatment: Method of treating bacterial infections
Dosage: SOLUTION;INTRAVENOUS, ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic